Published in Gene Therapy Weekly, May 18th, 2006
Digene has made an up-front payment to Asuragen and will make additional payments based on regulatory milestones. Additional financial details of the agreement were not disclosed.
Under the agreement, Digene will have the exclusive rights to market and distribute Asuragen's Signature CF products world-wide. In addition, Asuragen will develop, also...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.